FDA Approves Xocova for COVID-19 Postexposure Prophylaxis

MONDAY, June 8, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older.Xocova is approved as a five-day, oral regimen with three tablets taken on day 1 (375 mg) and one tablet taken on days 2 through 5 (125 mg).The approval is based on results from the phase 3 SCORPIO-PEP trial, which included 2,387 study participants with a negative local screening test for severe acute respiratory syndrome coronavirus 2 infection and no symptoms at the time of enrollment, but who had been exposed to a person living in their household with symptomatic COVID-19. Those randomly assigned to Xocova had a significantly lower risk for symptomatic COVID-19 (67 percent lower), the primary outcome, through day 10, compared with placebo. The trial also showed that Xocova was generally well tolerated, with similar rates of adverse events observed across groups (15.1 versus 15.5 percent [placebo]). The most common adverse events included headache, diarrhea, and cough, which occurred in ≥1 percent in the Xocova group and at a greater frequency than in the placebo group."The FDA approval of Xocova provides an important new approach to preventing COVID-19, which continues to impact lives," Frederick Hayden, M.D., from the University of Virginia School of Medicine, said in a statement. "The PEP strategy has the potential to benefit anyone who does not want to get COVID-19. It could be useful not only in household settings but also in other exposure circumstances, such as outbreaks in nursing homes, chronic or acute care facilities, and following travel-related exposures."Approval of Xocova was granted to Shionogi.More Information.Sign up for our weekly HealthDay newsletter

FDA Approves Xocova for COVID-19 Postexposure Prophylaxis

Related Stories

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

Home-Delivered Medical Meals Reduce ER Visits, Save Money

FDA Blocked Melanoma Drug As Confusion Reigned Under Makary

FDA Approves AI Sepsis Tool That Detects Infection Hours Earlier Than Doctors